300497.SZ Stock Analysis
30
Uncovered
Jiangxi Fushine Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi and currently employs 1,849 full-time employees. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.